Skip to main content

Biomarkers Market: USD 97.51 Billion by 2026 at CAGR of 12.1%

Written by Customer Service on . Posted in Mergers And Acquisitions.

According to Fortune Business Insights, the global Biomarkers Market size is projected to reach USD 97.51 Billion in 2026, at CAGR of 12.1% during forecast period; Increasing Usage in Disease Diagnostics to Propel Growth.

Pune, India, June 06, 2022 (GLOBE NEWSWIRE) — The global Biomarkers Market is set to gain traction from their increasing usage in a wide variety of applications, namely, drug discovery and development, safety assessment, and medicine. Besides, numerous biotech and pharmaceutical companies are persistently investing huge sums in the research and development activities. The increasing prevalence of cancer is also one of the crucial factors that would affect the market positively during the forecast period.

The above information is given by Fortune Business Insights™ in a recent study, titled, “Biomarkers Market Size, Share & Industry Analysis, By Indication (Oncology, Cardiology, Neurology, and Others), By End User (Pharmaceutical & Biotechnology Companies, Diagnostics & Research Laboratories, Hospitals & Specialty Clinics, and Others), and Regional Forecast, 2019-2026.” The study further mentions that the biomarker market size was USD 39.10 billion in 2018 and is projected to reach USD 97.51 billion by 2026, thereby exhibiting a CAGR of 12.1% during the forecast period.

Request a Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/biomarkers-market-102173


Key Industry Development

November 2019: DiamiR, a provider of unique blood-based diagnostic tests, declared that it received an award worth USD 492,000 from the Alzheimer’s Drug Discovery Foundation (ADDF). It would help the company in supporting a project called ‘Circulating brain-enriched microRNAs as peripheral biomarkers of neurodegeneration.’

May 2017: F. Hoffmann-La Roche AG, a multinational healthcare company, based in Basel, announced that it has bagged the U.S. FDA approval for biomarker assay. It will be used to deliver PD-L1 status for patients with metastatic urothelial carcinoma (mUC).

Report Scope & Segmentation:

Report CoverageDetails
Forecast Period2019-2026
Forecast Period 2019 to 2026 CAGR12.1%
2026 Value ProjectionUSD 97.51 billion
Base Year2018
Market Size in 2018USD 39.10 billion
Historical Data for2015-2017
No. of Pages110
Segments coveredBy Indication, By End User, By Geography
Growth DriversIncrease in the diagnostic applications of biomarkers is one of the major factors propelling the growth of the biomarker industry.
The rising demand for personalized medicine is one of the major factors driving the demand for biomarkers hence fueling the growth of the market.


Market Growth Drivers

Increasing Demand for Personalized Medicine to Accelerate Growth

Biomarkers are increasingly used in disease diagnostics. They also play an important role in development of personalized medicine for several disease conditions. Disease diagnosis and treatment procedures possess certain limitations and because of this, the concept of personalized medicine is becoming popular nowadays. Patients suffering from immunological disorders and cancer are rapidly inclining towards customized treatment options based on their genetic and clinical features. It would propel the biomarkers market growth during the forecast period.


Click here to get the short-term and long-term impact of COVID-19 on this Market:

https://www.fortunebusinessinsights.com/biomarkers-market-102173


Highlights of the Report

  • In-depth information about the biomarkers market trends, growth opportunities, challenges, drivers, and barriers.
  • List of all the segments and niche regions present in the market.
  • Extensive analysis of the competitive landscape, including new contracts, agreements, mergers and acquisitions, innovative product launches, collaborations, and investments.
  • Details about the strategies used by prominent companies to enhance their businesses.

Segments

Oncology Segment to Grow Steadily Backed by Rising Prevalence of Chronic Diseases

In terms of indication, the market is grouped into oncology, cardiology, neurology and others. Out of these, the oncology segment dominated the market in 2018. This growth is attributable to the increasing cases of cancer. Growing demand for personalized medicine in diagnosis and treatment of cancer, along with increasing number of new biomarker based assays and tests being introduced by market players, is propelling the growth of oncology segment. Rising prevalence of neurological disorders and increasing investment by key market players in the development of neurology biomarkers are is one of the major factor anticipated to drive the growth of the segment at faster rate.


Quick Buy – Biomarkers Market:

https://www.fortunebusinessinsights.com/checkout-page/102173


Regional Insights

Rising Investment by Key Players to Favor Growth in North America

The market is geographically fragmented into Asia Pacific, North America, Latin America, the Middle East and Africa, and Europe. Out of these regions, in 2018, North America held USD 14.80 billion biomarkers market revenue and is expected to grow by showcasing a high CAGR in the coming years. This is likely to occur because of the rising investments by several industry giants in the development of biomarkers. The region will be followed by Europe.

Competitive Landscape

DiamiR Receives Award from ADDF; Roche Bags FDA Approval for Biomarker Assay

The market consists of several big, medium, and small enterprises that are aiming to gain more biomarkers market share by developing state-of-the-art products and gaining fast track approvals. Various companies are also striving to receive funds from renowned agencies for the creation of new biomarkers.

The Report Lists the Key Companies in the Global Biomarkers Market

  • Abbott
  • R&D System
  • F. Hoffmann-La Roche Ltd.
  • R&D System
  • Thermo Fisher Scientific
  • Axon Medchem
  • Bio-Rad Laboratories, Inc.
  • BioVision Inc.
  • Sino Biological Inc.
  • CENTOGENE N.V.
  • Other key market players


Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/biomarkers-market-102173


Table of Contents

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • New Product Launches, by Key Market Players
    • Prevalence by Disease Indication, By Key Countries/ Region, 2018
    • Incidence of Cancer, By Key Countries/ Key Region,2018
    • Key industry Developments – Mergers, Acquisitions and Partnerships
    • Overview of Biomarkers In Personalized Medicine
  • Global Biomarkers Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Indication
      • Oncology
      • Cardiology
      • Neurology
      • Others
    • Market Analysis, Insights and Forecast – By End User
      • Pharmaceutical & Biotechnology Companies
      • Diagnostics & Research Laboratories
      • Hospitals & Specialty Clinics
      • Others
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa
  • North America Biomarkers Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Indication
      • Oncology
      • Cardiology
      • Neurology
      • Others
    • Market Analysis, Insights and Forecast – By End User
      • Pharmaceutical & Biotechnology Companies
      • Diagnostics & Research Laboratories
      • Hospitals & Specialty Clinics
      • Others
    • Market Analysis, Insights and Forecast – By Country
      • U.S.
      • Canada
  • Europe Biomarkers Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Indication
      • Oncology
      • Cardiology
      • Neurology
      • Others
    • Market Analysis, Insights and Forecast – By End User
      • Pharmaceutical & Biotechnology Companies
      • Diagnostics & Research Laboratories
      • Hospitals & Specialty Clinics
      • Others

ToC Continued…


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/biomarkers-market-102173


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.